Q1 Earnings Forecast for Merus Issued By Leerink Partnrs

Merus (NASDAQ:MRUS) – Equities researchers at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Merus in a research note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the biotechnology company will earn ($1.18) per share for the quarter. The consensus estimate for Merus’ current full-year earnings is ($3.89) per share. Leerink Partnrs also issued estimates for Merus’ Q2 2025 earnings at ($1.26) EPS and Q3 2025 earnings at ($1.30) EPS.

A number of other research analysts have also recently weighed in on MRUS. UBS Group began coverage on shares of Merus in a research note on Thursday, October 24th. They set a “buy” rating and a $72.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $85.00 price objective on shares of Merus in a research note on Monday, December 2nd. The Goldman Sachs Group started coverage on Merus in a research note on Thursday, November 21st. They set a “buy” rating and a $73.00 target price on the stock. Guggenheim restated a “buy” rating and issued a $109.00 price target (down from $111.00) on shares of Merus in a research note on Tuesday, December 3rd. Finally, Citigroup lifted their price objective on shares of Merus from $89.00 to $97.00 and gave the company a “buy” rating in a research report on Monday, December 9th. One analyst has rated the stock with a sell rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Merus has a consensus rating of “Buy” and an average price target of $85.64.

Merus Stock Performance

Shares of MRUS opened at $41.54 on Friday. The business has a 50-day simple moving average of $42.24 and a two-hundred day simple moving average of $47.86. Merus has a 52 week low of $35.67 and a 52 week high of $61.61.

Institutional Trading of Merus

Several institutional investors have recently made changes to their positions in the company. Avior Wealth Management LLC acquired a new stake in Merus in the 4th quarter valued at approximately $76,000. nVerses Capital LLC grew its stake in shares of Merus by 750.0% in the third quarter. nVerses Capital LLC now owns 1,700 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 1,500 shares in the last quarter. US Bancorp DE purchased a new stake in shares of Merus in the 3rd quarter valued at $103,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Merus by 24.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,467 shares of the biotechnology company’s stock worth $118,000 after acquiring an additional 489 shares in the last quarter. Finally, MML Investors Services LLC purchased a new position in Merus during the 3rd quarter valued at about $206,000. Hedge funds and other institutional investors own 96.14% of the company’s stock.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.